title: 31P NMR spectroscopy and HbO2 cryospectrophotometry in prediction of tumor radioresistance caused by hypoxia.
abstract: The aim of this study was to search for possible relationships between the fraction of radiobiologically hypoxic cells in tumors and their 31P NMR spectral parameters and intracapillary HbO2 saturations. Four different tumor lines, two murine sarcomas (KHT, RIF-1) and two human ovarian carcinoma xenografts (MLS, OWI), were used. When tumor volume increased from about 200 mm3 to about 2000 mm3, hypoxic fraction increased from 12 to 23% for the KHT line, from 0.9 to 1.7% for the RIF-1 line, and from 9 to 28% for the MLS line. The OWI line showed similar hypoxic fractions at 200 (17%) and 2000 mm3 (15%). Tumor bioenergetic status decreased, that is, the inorganic phosphate (Pi) resonance increased and the phosphocreatine (PCr) and nucleoside triphosphate beta (NTP beta) resonances decreased, with increasing tumor volume for the KHT, RIF-1, and MLS lines, whereas the OWI line did not show any changes in the 31P NMR spectral parameters during tumor growth. Similarly, tumor HbO2 saturation status, that is, the fraction of vessels with HbO2 saturation above 30%, decreased with increasing tumor volume for the KHT, RIF-1, and MLS lines, but remained unchanged during tumor growth for the OWI line. Although the data indicated a relationship between hypoxic fraction and tumor bioenergetic status as well as tumor HbO2 saturation status within a specific line during tumor growth, there was no correlation between hypoxic fraction and tumor bioenergetic status or tumor HbO2 saturation status across the four tumor lines. This may have occurred because cell survival time under hypoxic stress as well as fraction of non-clonogenic, but metabolically active hypoxic cells differed among the tumor lines. This indicates that 31P NMR spectroscopy and HbO2 cryospectrophotometry data have to be supplemented with other data to be useful in prediction of tumor radioresistance caused by hypoxia.
authors.affiliation: Experimental Therapeutics Division, University of Rochester Cancer Center, NY 14642.
authors.forename: E K
authors.initials: EK
authors.lastname: Rofstad
authors.forename: P
authors.initials: P
authors.lastname: DeMuth
authors.forename: B M
authors.initials: BM
authors.lastname: Fenton
authors.forename: T L
authors.initials: TL
authors.lastname: Ceckler
authors.forename: R M
authors.initials: RM
authors.lastname: Sutherland
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy; D002470:Cell Survival / Q000528:radiation effects; D005260:Female; D005615:Freezing; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000473:pathology / Q000532:radiotherapy*; D010051:Ovarian Neoplasms / Q000473:pathology / Q000532:radiotherapy; D010100:Oxygen / Q000378:metabolism*; D010108:Oxyhemoglobins / Q000032:analysis*; D011836:Radiation Tolerance; D012513:Sarcoma, Experimental / Q000473:pathology / Q000532:radiotherapy; D013053:Spectrophotometry / Q000379:methods; D014407:Tumor Cells, Cultured / Q000528:radiation effects
chemical_list: D010108:Oxyhemoglobins; D010100:Oxygen